Tarlige Drug Interactions

Mirogabalin is predominantly excreted by renal glomerular filtration and tubular secretion. The Transporters involved in the secretion of mirogabalin are organic anion transporter (OAT) 1, OAT3, organic cation transporter (OCT) 2, H⁺/organic cation antiporter (MATE) 1, and MATE2-K. Mirogabalin is also metabolized by UDP-glucuronosyltransferases (UGTs). (See Table 10.)

Click on icon to see table/diagram/image

In vitro study data: Mirogabalin was not metabolized by CYP but was metabolized by UGT1A3, UGT1A4, UGT1A9, UGT2B4, UGT2B7 and UGT2B17.
Mirogabalin was secreted from the kidney and was suggested to be a substrate for OAT1, OAT3, OCT2, MATE1, and MATE2-K.
Mirogabalin did not inhibit or induce major human CYP molecular species, and did not inhibit activities of drug transporters (OAT1, OAT3, OCT1, OCT2, OATP1B1, OATP1B3, MATE1, and MATE2-K). Mirogabalin also did not inhibit activities of P-glycoprotein (P-gp) or breast cancer resistance protein (BCRP).
In clinical study data: Co-administration of probenecid (500 mg) with TARLIGE (15 mg) increased the Cmax and AUClast of TARLIGE by 29% and 76%, respectively.
Co-administration of cimetidine (400 mg) with TARLIGE (15 mg) increased the Cmax and AUClast of TARLIGE by 17% and 44%, respectively.
Co-administration of TARLIGE with ethanol or lorazepam had no notable effect on the pharmacokinetics of TARLIGE or these drugs. Co-administration of TARLIGE in with these drugs decreased attention and balance-function more profoundly than monotherapy with TARLIGE.
Co-administration of TARLIGE with tramadol had no notable effect on the pharmacokinetics of TARLIGE or tramadol.